Role of Epigallocatechin for the Prevention of Infections in Patients Treated with ImmunoSuppressive Therapy

Role of Epigallocatechin for the Prevention of Infections in Patients Treated with ImmunoSuppressive Therapy - Role of EpigalloCAtechin for the prevention of infections in patients treated with immunoSuppressive Therapy (RECAST)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013344

Enrollment

Registered

2014-03-07

Start date

2012-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Collagen Vascular Diseases

Interventions

Roasted barley tea containing high epigallocatechin Roasted barley tea without epigallocatechin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients initiated with more than 30mg/day of prednisolone for the treatment of collagen vascular diseases

Exclusion criteria

Exclusion criteria: Patients already treated with more than 10mg/day of prednisolone

Design outcomes

Primary

Measure	Time frame
The events of bacterial and viral infections	—

Secondary

Measure	Time frame
The values of biomarkers suggesting viral and bacterial infections	—

Countries

Japan

Contacts

Public ContactTohru Takeuchi

Osaka Medical College Department of Internal Medicine (I)

t-takeuchi@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026